SCHEDULE 13G: Millennium Management Reduces Stake in Verve Therapeutics Below 5% Threshold

Millennium Management LLC and its affiliates have reported a reduction in their beneficial ownership of Verve Therapeutics, Inc. common stock, falling below the 5% reporting threshold after briefly exceeding it.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G regarding their beneficial ownership of Verve Therapeutics, Inc. Common Stock.
• The reporting persons collectively held 4,327,227 shares, representing 4.9% of the class.
• On April 22, 2025, the reporting persons acquired beneficial ownership of more than 5% of Verve Therapeutics' outstanding Common Stock.
• However, by the filing date of April 28, 2025, they had ceased to be beneficial owners of more than 5% of the outstanding Common Stock, indicating a reduction in their stake.
• The filing confirms that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor, suggesting a potential decrease in confidence or a strategic re-evaluation of the position.

Negatives

• The reporting persons, Millennium Management LLC and its affiliates, reduced their beneficial ownership in Verve Therapeutics, Inc. from over 5% to 4.9% between April 22, 2025, and April 28, 2025, which could signal a decrease in conviction or a strategic divestment.

Risks

• A reduction in stake by a significant institutional investor like Millennium Management could be perceived negatively by the market, potentially leading to decreased investor confidence.
• The rapid change in ownership (briefly exceeding 5% then dropping below) might indicate volatility in the investor's position or a lack of long-term commitment.

Future Outlook

This filing does not contain forward-looking statements or guidance from Verve Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This Schedule 13G filing reflects a change in a significant institutional investor's position in a biotechnology company. Such filings are common in the investment landscape and can sometimes signal shifts in investor sentiment towards specific companies or sectors, though this particular filing indicates a passive investment with no intent to influence control.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by Millennium Management as a negative signal, potentially impacting investor confidence and the company's stock price.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this passive ownership filing, as it does not indicate operational or strategic changes within Verve Therapeutics.

Key Dates

Recommendation

Keywords

Verve Therapeutics, Millennium Management, Schedule 13G, beneficial ownership, common stock, institutional investment, stake reduction